JANX Insider Trading
Insider Ownership Percentage: 29.40%
Insider Buying (Last 12 Months): $53,700,000.00
Insider Selling (Last 12 Months): $188,270,185.71
Janux Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Janux Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Janux Therapeutics Share Price & Price History
Current Price: $44.76
Price Change: ▼ Price Decrease of -0.032 (-0.07%)
As of 01/31/2025 02:05 PM ET
Janux Therapeutics Insider Trading History
SEC Filings (Institutional Ownership Changes) for Janux Therapeutics (NASDAQ:JANX)
75.39% of Janux Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at JANX by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Janux Therapeutics Institutional Trading History
Data available starting January 2016
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More on Janux Therapeutics
Today's Range
Now: $44.76
52 Week Range
Now: $44.76
Volume
279,837 shs
Average Volume
1,114,121 shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.23
Who are the company insiders with the largest holdings of Janux Therapeutics?
Who are the major institutional investors of Janux Therapeutics?
Which institutional investors are selling Janux Therapeutics stock?
In the last quarter, JANX stock was sold by these institutional investors:
- Nisa Investment Advisors LLC
- Chicago Partners Investment Group LLC
Within the last year, company insiders that have sold Janux Therapeutics company stock include:
- Ra Capital Management, LP (Director)
- Ventures Xi LP Avalon (Major Shareholder)
- Jay Lichter (Director)
- Tighe Reardon (CFO)
- David Alan Campbell (CEO)
Learn More investors selling Janux Therapeutics stock.
Which institutional investors are buying Janux Therapeutics stock?
In the last quarter, JANX stock was acquired by institutional investors including:
- abrdn plc
- Lester Murray Antman dba SimplyRich
- Legato Capital Management LLC
- Chicago Capital LLC
- Avanza Fonder AB
- China Universal Asset Management Co. Ltd.
- Rhumbline Advisers
During the last year, these company insiders have bought Janux Therapeutics stock:
- Ra Capital Management, LP (Director)
- Ventures Xi LP Avalon (Major Shareholder)
Learn More investors buying Janux Therapeutics stock.